Orbimed Advisors Llc Sells 474,676 Shares of Roka Bioscience, Inc. (ROKA) Stock
Posted by Amber O'Connor on Oct 4th, 2017
Roka Bioscience logoRoka Bioscience, Inc. (NASDAQ:ROKA) major shareholder Orbimed Advisors Llc sold 474,676 shares of the stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $0.72, for a total value of $341,766.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Orbimed Advisors Llc also recently made the following trade(s):
On Wednesday, September 27th, Orbimed Advisors Llc sold 127,601 shares of Roka Bioscience stock. The shares were sold at an average price of $0.98, for a total value of $125,048.98.
On Wednesday, August 23rd, Orbimed Advisors Llc sold 1,100 shares of Roka Bioscience stock. The shares were sold at an average price of $1.50, for a total value of $1,650.00.
On Thursday, August 24th, Orbimed Advisors Llc sold 14,300 shares of Roka Bioscience stock. The shares were sold at an average price of $1.50, for a total value of $21,450.00.
On Tuesday, August 22nd, Orbimed Advisors Llc sold 75,276 shares of Roka Bioscience stock. The shares were sold at an average price of $1.52, for a total value of $114,419.52.
Roka Bioscience, Inc. (NASDAQ ROKA) opened at 0.67 on Wednesday. The company has a 50 day moving average price of $1.16 and a 200 day moving average price of $2.54. The firm’s market capitalization is $3.35 million. Roka Bioscience, Inc. has a 12 month low of $0.66 and a 12 month high of $8.50.
An institutional investor recently raised its position in Roka Bioscience stock. Sabby Management LLC boosted its holdings in Roka Bioscience, Inc. (NASDAQ:ROKA) by 6.5% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 389,136 shares of the medical research company’s stock after purchasing an additional 23,916 shares during the quarter. Sabby Management LLC owned about 7.77% of Roka Bioscience worth $1,374,000 at the end of the most recent quarter. 66.51% of the stock is owned by institutional investors.
Roka Bioscience Company Profile
Roka Bioscience, Inc is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications.
